KisoJi Biotechnology Overview
- Year Founded
-
2009
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$29.9M
- Investors
-
8
KisoJi Biotechnology General Information
Description
Developer of therapeutic antibody discovery technologies and multi-specific biologics designed for oncology and inflammatory disease treatment. The company's platform integrates multi-species transgenic mice to generate diverse single-domain antibodies with artificial intelligence paratope mapping and structural screening tools to identify rare functional candidates against difficult-to-drug targets, enabling the pharmaceutical industry and clinical researchers to access specific, non-toxic, and modular therapeutic agents that utilize immune cell recruitment for patient outcomes in hard-to-treat solid and hematologic cancers.
Contact Information
Website
www.kisojibiotech.comCorporate Office
- 3576 Aenue Du Parc
- Suite 4310
- Montreal, Quebec H2X 2J1
- Canada
Corporate Office
- 3576 Aenue Du Parc
- Suite 4310
- Montreal, Quebec H2X 2J1
- Canada
KisoJi Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 29-Oct-2024 | $29.9M | Completed | Clinical Trials - Phase 1 | ||
| 2. Later Stage VC | 13-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 1. Later Stage VC (Series A1) | 10-Oct-2016 | $4M | $4M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
KisoJi Biotechnology Patents
KisoJi Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024402016-A1 | System and method for mapping molecules into interfaces | Pending | 13-Dec-2023 | ||
| EP-4824794-A1 | System and method for mapping molecules into interfaces | Pending | 13-Dec-2023 | ||
| US-12749558-B2 | System and method for mapping molecules into interfaces | Active | 13-Dec-2023 | ||
| US-20250201352-A1 | System and method for mapping molecules into interfaces | Active | 13-Dec-2023 | ||
| WO-2025123146-A1 | System and method for mapping molecules into interfaces | Inactive | 13-Dec-2023 | G16B15/20 |
KisoJi Biotechnology Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| adMare Bioinnovations | Corporation | Minority | ||
| Investissement Quebec | PE/Buyout | Minority | ||
| Accel-Rx | Accelerator/Incubator | Minority | ||
| BDC Capital | Growth/Expansion | Minority | ||
| Centre for Commercialization of Regenerative Medicine | Corporation | Minority |
KisoJi Biotechnology FAQs
-
When was KisoJi Biotechnology founded?
KisoJi Biotechnology was founded in 2009.
-
Where is KisoJi Biotechnology headquartered?
KisoJi Biotechnology is headquartered in Montreal, Canada.
-
What industry is KisoJi Biotechnology in?
KisoJi Biotechnology’s primary industry is Drug Discovery.
-
Is KisoJi Biotechnology a private or public company?
KisoJi Biotechnology is a Private company.
-
What is KisoJi Biotechnology’s current revenue?
The current revenue for KisoJi Biotechnology is .
-
How much funding has KisoJi Biotechnology raised over time?
KisoJi Biotechnology has raised $33.9M.
-
Who are KisoJi Biotechnology’s investors?
adMare Bioinnovations, Investissement Quebec, Accel-Rx, BDC Capital, and Centre for Commercialization of Regenerative Medicine are 5 of 8 investors who have invested in KisoJi Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process